U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H77NO17.C4H6O6
Molecular Weight 1066.1869
Optical Activity UNSPECIFIED
Defined Stereocenters 23 / 23
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TYLOSIN TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]1(C[C@@](C)(O)[C@@H](O)[C@H](C)O1)O[C@@H]2[C@@H](C)O[C@@]([H])(O[C@H]3[C@@H](CC=O)C[C@@H](C)C(=O)\C=C\C(C)=C\[C@H](CO[C@@H]4O[C@H](C)[C@@H](O)[C@@H](OC)[C@H]4OC)[C@@H](CC)OC(=O)C[C@@H](O)[C@@H]3C)[C@H](O)[C@H]2N(C)C

InChI

InChIKey=ICVKYYINQHWDLM-KBEWXLTPSA-N
InChI=1S/C46H77NO17.C4H6O6/c1-13-33-30(22-58-45-42(57-12)41(56-11)37(52)26(5)60-45)18-23(2)14-15-31(49)24(3)19-29(16-17-48)39(25(4)32(50)20-34(51)62-33)64-44-38(53)36(47(9)10)40(27(6)61-44)63-35-21-46(8,55)43(54)28(7)59-35;5-1(3(7)8)2(6)4(9)10/h14-15,17-18,24-30,32-33,35-45,50,52-55H,13,16,19-22H2,1-12H3;1-2,5-6H,(H,7,8)(H,9,10)/b15-14+,23-18+;/t24-,25+,26-,27-,28+,29+,30-,32-,33-,35+,36-,37-,38-,39-,40-,41-,42-,43+,44+,45-,46-;1-,2-/m11/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C46H77NO17
Molecular Weight 916.1001
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 21 / 21
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.elanco.us/labels/Swine/Tylan_Soluble.pdf

Tylosin (trade names Tylocine, Tylan) is a bacteriostat feed additive used in veterinary medicine. It has a broad spectrum of activity against Gram-positive organisms and a limited range of Gram-negative organisms. It is found naturally as a fermentation product of Streptomyces fradiae. It is a macrolide antibiotic. Tylosin is used in veterinary medicine to treat bacterial infections in a wide range of species and has a high margin of safety. Tylosin is certified by the FDA but is only approved for use in livestock such as cattle, chickens, swine, and turkeys. The FDA has prohibited the use of tylosin in dogs and cats, except where it is specifically prescribed by a veterinarian. Tylosin has a bacteriostatic effect on susceptible organisms, caused by inhibition of protein synthesis through binding to the 50S subunit of the bacterial ribosome.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Mycoplasma sp. 1220 growth
Target ID: Staphylococcus aureus growth
Target ID: E. coli growth
Target ID: Streptococcus pneumoniae growth
Target ID: Pasteurella multocida growth
Target ID: Fusobacterium necrophorum growth
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Tylan 200

Approved Use

In beef cattle and non-lactating dairy cattle, Tylan 200 Injection is indicated for use in the treatment of bovine respiratory complex (shipping fever, pneumonia) usually associated with Pasteurella multocida and Actinomyces pyogenes; foot rot (necrotic pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum and metritis caused by Actinomyces pyogenes. In swine, Tylan 200 Injection is indicated for use in the treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed.

Launch Date

1.27543686E12
Curative
Tylan 200

Approved Use

In beef cattle and non-lactating dairy cattle, Tylan 200 Injection is indicated for use in the treatment of bovine respiratory complex (shipping fever, pneumonia) usually associated with Pasteurella multocida and Actinomyces pyogenes; foot rot (necrotic pododermatitis) and calf diphtheria caused by Fusobacterium necrophorum and metritis caused by Actinomyces pyogenes. In swine, Tylan 200 Injection is indicated for use in the treatment of swine arthritis caused by Mycoplasma hyosynoviae; swine pneumonia caused by Pasteurella spp; swine erysipelas caused by Erysipelothrix rhusiopathiae; swine dysentery associated with Treponema hyodysenteriae when followed by appropriate medication in the drinking water and/or feed.

Launch Date

1.27543686E12
PubMed

PubMed

TitleDatePubMed
Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study.
1989 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be given orally https://www.elanco.us/labels/Swine/Tylan_Soluble.pdf
BEEF CATTLE AND NON-LACTATING DAIRY CATTLE—Inject intramuscularly 8 mg per pound of body weight one time daily (1 mL per 6.25 pounds). Treatment should be continued 24 hours following remission of disease signs, not to exceed 5 days. SWINE—Inject intramuscularly 4 mg per pound of body weight (1 mL per 12.5 pounds) twice daily. Treatment should be continued 24 hours following remission of disease signs, not to exceed 3 days. Do not inject more than 5 mL per site.
Route of Administration: Intramuscular
In Vitro Use Guide
Tylosin yielded MIC50 value for Mycoplasma sp. 1220 strain isolated from geese in Hungary - 8 ug/ml
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:29:46 UTC 2023
Edited
by admin
on Wed Jul 05 22:29:46 UTC 2023
Record UNII
5P4625C51T
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TYLOSIN TARTRATE
GREEN BOOK   MART.   USP  
Common Name English
NSC-758961
Code English
TYLOSIN TARTRATE [USP-RS]
Common Name English
TYLAN SOLUBLE
Brand Name English
TYLOSIN TARTRATE [GREEN BOOK]
Common Name English
TYLOSIN, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)
Common Name English
PHARMASIN
Brand Name English
TYLAN INJECTABLE
Brand Name English
TYLOSIN TARTRATE [USP MONOGRAPH]
Common Name English
TYLOSIN TARTRATE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C261
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
Code System Code Type Description
NSC
758961
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
RS_ITEM_NUM
1703850
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
ECHA (EC/EINECS)
215-781-5
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
SMS_ID
300000023717
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
CAS
1405-54-5
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
NON-SPECIFIC STOICHIOMETRY
EPA CompTox
DTXSID3045938
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
DRUG BANK
DBSALT001663
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
FDA UNII
5P4625C51T
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
RXCUI
996012
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C84236
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
PUBCHEM
60196281
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
CAS
74610-55-2
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
DAILYMED
5P4625C51T
Created by admin on Wed Jul 05 22:29:46 UTC 2023 , Edited by admin on Wed Jul 05 22:29:46 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY